Top Markets
Coin of the day
Exopharm Limited Exopharm Limited

Exopharm Limited

EX1
주식 순위 #39130
Exopharm Limited is an Australian clinical-stage firm dedicated to developing... Exopharm Limited is an Australian clinical-stage firm dedicated to developing groundbreaking therapeutics utilizing extracellular vesicles (EVs). Its core technologies include an extracellular vesicle positioning system (EVPS), which facilitates the precise targeting of exosomes by attaching specific molecules to their surface, guiding them to particular tissues or cell types. Another innovation is oligonucleotide packing, designed to optimize therapeutic delivery by preferentially loading specific RNA molecules into exosomes as medicinal cargo. Additionally, Exopharm employs ligand-based exosome affinity purification for effectively isolating and refining exosomes from biological fluids such as blood and cell culture media. The company's engineered EV product portfolio features Fortrexo CoV, aimed at treating SARS-CoV-2 infections; Cognevo, developed for neurodegenerative diseases; and PlexoDox, intended for cancer treatment. Exopharm Limited also maintains a research collaboration with Showa Denko Materials Co., Ltd. The company was founded in 2013 and is headquartered in Melbourne, Australia.
주가
$0.00700343
마지막 동기화: 2023-10-30
시가총액
$637.31K
변동 (1일)
0.50%
변동 (1년)
0.00%
국가
AU
거래 Exopharm Limited (EX1)

카테고리

Exopharm Limited (EX1)의 EPS
2026 기준 EPS TTM: 0
Exopharm Limited의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 0입니다. 2026년 말에는 회사의 EPS가 0였으며, 이는 2026년의 EPS 0와 동일입니다.
Exopharm Limited의 EPS 기록 (2026 ~ 2026)
매년 말의 EPS
연도 EPS 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 EPS